Summary of medicine characteristics - Equilis Prequenza Te
SUMMARY OF PRODUCT CHARACTERISTICS
-
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
Equilis Prequenza Te suspension for injection for horses
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose of 1 ml contains:Active substances:
Equine influenza virus strains: A/equine-2/ South Africa/4/03 A/equine-2/ Newmarket/2/93
50 AU1
50 AU
Tetanus toxoid 40 Lf2
-
1 Antigenic units
-
2 Flocculation equivalents; corresponds with > 30 lU/ml guinea pig serum in the Ph.Eur. potency test
Adjuvants:
Iscom-Matrix containing:
| Purified Saponin | 375 micrograms |
| Cholesterol | 125 micrograms |
| Phosphatidylcholine | 62.5 micrograms |
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Suspension for injection.
Clear opalescent suspension.
4. CLINICAL PARTICULARS4.1 Target species
Horses
-
4.2 Indications for use, specifying the target species
Active immunisation of horses from 6 months of age against equine influenza to reduce clinical signs and virus excretion after infection, and active immunisation against tetanus to prevent mortality.
| Influenza Onset of immunity: | 2 weeks after the primary vaccination course |
| Duration of immunity: | 5 months after the primary vaccination course 12 months after the first revaccination |
| Tetanus Onset of immunity: | 2 weeks after the primary vaccination course |
| Duration of immunity: | 17 months after the primary vaccination course 24 months after the first revaccination |
4.3 Contraindications
None.
-
4.4 Special warnings for each target species
Foals should not be vaccinated before the age of 6 months, especially when born to mares that were revaccinated in the last two months of gestation, because of possible interference by maternally derived antibodies.
Vaccinate healthy animals only.
-
4.5 Special precautions for use
Special precautions for use in animals
Not applicable.
Special precautions to be taken by the person administering the veterinary medicinal product to animals In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
-
4.6 Adverse reactions (frequency and seriousness)
A diffuse hard or soft swelling (max. diameter 5 cm) may rarely occur at the injection site, regressing within 2 days. Pain at the injection site can occur in rare cases which may result in temporary functional discomfort (stiffness). A local reaction exceeding 5 cm and possibly persisting longer than 2 days may occur in very rare cases. Fever, sometimes accompanied by lethargy and inappetence, may in very rare cases occur for 1 day, and up to 3 days in exceptional circumstances.
The frequency of adverse reactions is defined using the following convention:
-
– very common (more than 1 in 10 animals treated displaying adverse reaction(s)
-
– common (more than 1 but less than 10 animals in 100 animals treated)
-
– uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
-
– rare (more than 1 but less than 10 animals in 10,000 animals treated)
-
– very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
-
4.7 Use during pregnancy, lactation or lay
Can be used during pregnancy and lactation.
4.8 Interaction with other medicinal products and other forms of interaction
Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day but not mixed with Tetanus Serum from Intervet (see section 4.9).
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the product mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
-
4.9 Amounts to be administered and administration route
Intramuscular use.
Allow the vaccine to reach room temperature before use.
Vaccination schedule :
Primary vaccination course
Administer one dose (1 ml), strictly intramuscularly, according to the following schedule:
- • Primary vaccination course: first injection from 6 months of age, second injection 4 weeks later
Revaccination
Influenza
It is recommended that a single booster dose should only be administered to horses that have already received a primary vaccination course using vaccines that contain the same types of equine influenza virus included in this vaccine. A primary vaccination course may be considered necessary in horses that have not been suitably primed.
The first revaccination (third dose) against equine influenza is given 5 months after the primary vaccination course. This revaccination results in immunity to equine influenza lasting at least 12 months.
The second revaccination is given 12 months after the first revaccination.
The alternate use, at 12 months interval, of a suitable vaccine against equine influenza, containing the strains A/equine-2/South Africa/4/03 and A/equine-2/Newmarket-2/93, is recommended to maintain immunity levels for the influenza component (see scheme).
Tetanus
The first revaccination is given not later than 17 months after the primary vaccination course. Thereafter a maximum interval of two years is recommended (see scheme).
V1 V2 5 V3 12 V4 12 V5 12 V6
0 1 6 18 30 42 months
Prequenza Prequenza Prequenza Prequenza Te Prequenza Prequenza Te
Te Te
In case of increased infection risk or insufficient colostrum intake, an additional initial injection can be given at the age of 4 months followed by the full vaccination programme (Primary vaccination course at 6 months of age and 4 weeks later).
Concurrent active and passive immunisation (emergency vaccination)
The vaccine can be used together with Tetanus-Serum from Intervet for treatment of injured horses that have not been immunised against tetanus. In that case, the first dose (V1) of vaccine can be given concurrently with the appropriate prophylactic dose of Tetanus-Serum from Intervet at a separate injection site, using separate syringes and needles. This will lead to a passive protection against tetanus for at least 21 days after concurrent administration. The second dose of the vaccine (V2) should be administered 4 weeks later. A third vaccination with Equilis Prequenza Te should be repeated at least four weeks later. Concurrent use of Equilis Prequenza Te and Tetanus-Serum from Intervet may reduce active immunity against tetanus compared to horses vaccinated with Equilis Prequenza Te in the absence of tetanus antitoxin serum.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
Following the administration of a double dose of vaccine, no side-effects other than those described under section 4.6 have been observed except for some depression at the day of vaccination
-
4.11 Withdrawal period(s)
Zero days.
-
5. IMMUNOLOGICAL PROPERTIES
Pharmacotherapeutic group: Immunologicals for Equidae, inactivated viral and inactivated bacterial vaccines ATC-vet code: QI05AL01
To stimulate active immunity against Equine influenza and tetanus in horses.
6. PHARMACEUTICAL PARTICULARS6.1 List of excipients
Phosphate buffer, traces of thiomersal, traces of formaldehyde
6.2 Major incompatibilities
Do not mix with any other veterinary medicinal product.
6.3 Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
6.4 Special precautions for storage
Store in a refrigerator (at 2 °C – 8 °C).
Do not freeze.
Protect from light.
-
6.5 Nature and composition of immediate packaging
Type I glass vials of 1 ml (1 dose) closed with a halogenobutyl rubber stopper and sealed with an aluminium cap.
Type I glass pre-filled syringes of 1 ml (1 dose), containing a plunger with a halogenobutyl end and closed with a halogenobutyl stopper.
Package sizes :
Cardboard box with 10 glass vials of 1 ml (1 dose).
Cardboard box(es) with 1, 5 or 10 pre-filled syringes of 1 ml (1 dose) with needles.
Not all pack sizes may be marketed.
-
6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products
7. MARKETING AUTHORISATION HOLDER
Intervet International B.V.
Wim de Korverstraat 35
5831 AN Boxmeer
The Netherlands
8. MARKETING AUTHORISATION NUMBER(S)
EU/2/05/057/001–004
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Date of first authorisation: 08 July 2005
Date of last renewal: 27 July 2010